Triple

T6003733
Position Surface form Disambiguated ID Type / Status
Subject Loxo Oncology E133655 entity
Predicate secondMajorProduct P68640 FINISHED
Object selpercatinib E561036 NE FINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: selpercatinib | Statement: [Loxo Oncology, secondMajorProduct, selpercatinib]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: selpercatinib
Context triple: [Loxo Oncology, secondMajorProduct, selpercatinib]
  • A. selpercatinib chosen
    Selpercatinib is a targeted cancer therapy drug that selectively inhibits RET kinase to treat certain RET-altered thyroid and non-small cell lung cancers.
  • B. larotrectinib
    Larotrectinib is a targeted cancer therapy that selectively inhibits TRK fusion proteins and is used to treat solid tumors harboring NTRK gene fusions regardless of tumor site.
  • C. Tagrisso
    Tagrisso is a targeted cancer therapy (osimertinib) used primarily to treat certain types of EGFR-mutated non-small cell lung cancer.
  • D. Vitrakvi
    Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
  • E. Imfinzi
    Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
PD Predicate disambiguation gpt-5-mini-2025-08-07 
Target predicate: secondMajorProduct
Context triple: [Loxo Oncology, secondMajorProduct, selpercatinib]
  • A. secondaryProducts
    Indicates that certain entities arise as secondary or byproduct outputs from a primary process, activity, or production.
  • B. secondaryBrand
    Indicates that one brand is a subordinate, supporting, or less prominent brand in relation to a primary brand.
  • C. primaryProduct
    Indicates that one entity is the main or most important product associated with, produced by, or offered by another entity.
  • D. secondaryTo
    Indicates that one condition, event, or factor occurs as a consequence of, or is caused by, another primary condition, event, or factor.
  • E. secondElement
    Indicates that one entity is the second element in an ordered pair, sequence, or collection relative to another entity.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69c00872444c8190bfaf1739dcec765c completed March 22, 2026, 3:19 p.m.
NER Named-entity recognition batch_69c04f0f63148190826198281dce3713 completed March 22, 2026, 8:20 p.m.
NED1 Entity disambiguation (via context triple) batch_69c11365741c819097a43a49dd2428c1 completed March 23, 2026, 10:18 a.m.
PD Predicate disambiguation batch_69c049e3316c819087ea635fa7ee8472 completed March 22, 2026, 7:58 p.m.
PDg Predicate description generation batch_69c04e8c5bfc8190b986a7071d1b23e3 completed March 22, 2026, 8:18 p.m.
Created at: March 22, 2026, 4:06 p.m.